Background and Objectives: Pharmacotherapy is a first-line treatment for bipolar disorder (BD), although half of individuals report suboptimal medication adherence. Medication adherence enhancement programs that are brief, person-specific, and remotely delivered may be an effective adjunct to treatment. The aim of this study was to qualitatively assess what individuals with BD who participated in a Customized Adherence Enhancement (CAE) program found most helpful and unhelpful about this program, focusing on elements most generalizable to medication adherence promotion. Materials and Methods: n = 14 participants with BD from the intervention arm of a randomized effectiveness trial of CAE vs. enhanced treatment–as-usual participated in one-on-one virtual, semi-structured interviews. Interviews were recorded, transcribed, and summarized using thematic content analysis to identify themes reflecting what was helpful and unhelpful about the program. Results: Participants identified six main themes reflecting impactful aspects of the medication adherence promotion program: practical tools (e.g., worksheets), self-awareness (e.g., identification of triggers), psychoeducation/content (e.g., specific CAE modules), emotional distress (e.g., difficult emotions arose during sessions), format (e.g., pros/cons of virtual format), and interventionist factors (e.g., rapport). Conclusions: Results provide participant-identified useful aspects of a remotely delivered, adjunctive medication adherence promotion program for individuals in treatment for BD in public-sector settings. Strategies for improvement and scale-up of the program include ensuring sufficient technologic and emotional support throughout the program. Future studies may investigate the longer-term impact of such interventions with multiple stakeholder input and consideration of diverse populations, settings, and cultural contexts.

Background and Objectives: There are known associations between bipolar disorder and obesity, but it has not been well characterized in older adults with bipolar disorder (OABD). This study aims to examine body mass index (BMI) and its clinical correlations in OABD. Materials and Methods: A secondary analysis was conducted using data from the Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE-BD) project, an international harmonized dataset of OABD cohorts. To examine the relationship between BMI and clinical characteristics (e.g., sex, psychiatric history, symptom severity, medication use, comorbidities), multivariable linear regression and multinomial logistic regression models with random effect for study cohort were used, with BMI as a continuous and as an ordinal (underweight vs. healthy weight vs. overweight vs. obese) dependent variable, respectively. Results: Of 1,226 OABD participants with BMI data, 405 (33.0%) were classified as overweight (BMI 25–29.99) and 462 (37.7%) as obese (BMI > 30). In linear regression models, higher BMI was associated with younger age, higher number of somatic comorbidities, and anticonvulsant use, while lower BMI was associated with lithium use. In logistic regression models, obesity was associated with cardiovascular comorbidity, musculoskeletal comorbidity and endocrine comorbidity. Conclusions: A high proportion of individuals with OABD are overweight or obese. Several demographic and clinical correlations of higher BMI were found, including younger age, higher number of medical comorbidities and anticonvulsant use. Clinicians should monitor and manage weight changes and associated comorbidities, and promote lifestyle and health interventions to minimize the risk of negative health outcomes associated with high BMI.